今年以来,创新药板块在多重利好因素的共同推动下持续受到市场关注。进入四季度,行业催化事件更趋密集:BD交易步入传统旺季,国家医保谈判正式启动,ESMO大会集中发布多项前沿科研成果。在此背景下,市场对板块能否开启新一轮行情的关注度显著提升。近期,创新药板块热度再度回升。回顾年内走势,国证港股通创新药指数自年初起表现强势,但自9月中旬以来,受获利盘了结与市场风格轮动影响,板块出现阶段性回调。当前,在...
Source Link今年以来,创新药板块在多重利好因素的共同推动下持续受到市场关注。进入四季度,行业催化事件更趋密集:BD交易步入传统旺季,国家医保谈判正式启动,ESMO大会集中发布多项前沿科研成果。在此背景下,市场对板块能否开启新一轮行情的关注度显著提升。近期,创新药板块热度再度回升。回顾年内走势,国证港股通创新药指数自年初起表现强势,但自9月中旬以来,受获利盘了结与市场风格轮动影响,板块出现阶段性回调。当前,在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.